Compare AUPH & FBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUPH | FBNC |
|---|---|---|
| Founded | 1993 | 1934 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2014 | 1995 |
| Metric | AUPH | FBNC |
|---|---|---|
| Price | $15.91 | $58.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $17.25 | ★ $62.25 |
| AVG Volume (30 Days) | ★ 1.1M | 173.4K |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.67% |
| EPS Growth | ★ 5075.00 | 45.65 |
| EPS | 0.25 | ★ 1.13 |
| Revenue | ★ $283,055,000.00 | $67,623,000.00 |
| Revenue This Year | $17.54 | $37.82 |
| Revenue Next Year | $15.74 | $2.30 |
| P/E Ratio | $64.08 | ★ $51.32 |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $7.29 | $40.01 |
| 52 Week High | $16.88 | $62.64 |
| Indicator | AUPH | FBNC |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 50.87 |
| Support Level | $14.28 | $55.54 |
| Resistance Level | $16.38 | $60.04 |
| Average True Range (ATR) | 0.68 | 1.38 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 63.10 | 56.72 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.